2,4-二氯-8-氟喹唑啉 | 959237-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2,4-二氯-8-氟喹唑啉
• 英文名称: 2,4-dichloro-8-fluoroquinazoline
• CAS: 959237-64-0
• 化学式: C₈H₃Cl₂FN₂
• 分子量: 217.03
• InChiKey: VXSUTXKJWJUPLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氯-8-氟喹唑啉 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 22.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors

  摘要：

  Novel 2,4-diaminoquinazoline derivatives originating from a virtual screening approach were designed, synthesized and their biological activities as heat shock protein 90 (Hsp90) inhibitors were evaluated. The prepared compounds exhibited significant anti-proliferative activities against DU-145, HT-29, HCT-116, A375P and MCF-7 cancer cell lines. The selected compounds were tested against Her2, a client protein of Hsp90, and showed significant reduction in Her2 protein expression. Compound 6b was found the most potent, reduced Her2 protein expression levels and induced Hsp70 protein expression levels significantly. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.117
• 作为产物：
  描述：

  8-氟-2,4(1H,3H)-喹唑啉二酮 在 三氯氧磷 作用下， 生成 2,4-二氯-8-氟喹唑啉
  参考文献：
  名称：

  Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors

  摘要：

  Novel 2,4-diaminoquinazoline derivatives originating from a virtual screening approach were designed, synthesized and their biological activities as heat shock protein 90 (Hsp90) inhibitors were evaluated. The prepared compounds exhibited significant anti-proliferative activities against DU-145, HT-29, HCT-116, A375P and MCF-7 cancer cell lines. The selected compounds were tested against Her2, a client protein of Hsp90, and showed significant reduction in Her2 protein expression. Compound 6b was found the most potent, reduced Her2 protein expression levels and induced Hsp70 protein expression levels significantly. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.117

文献信息

• [EN] INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF<br/>[FR] INHIBITEURS DE RÉPLICATION DU VIRUS DE LA GRIPPE, PROCÉDÉS D'APPLICATION ET UTILISATIONS ASSOCIÉES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2018033082A1

  公开（公告）日：2018-02-22

  A class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

  一类化合物作为流感病毒复制抑制剂，其制备方法，含有这些化合物的药物组合物，以及这些化合物和药物组合物在治疗流感中的用途。
• [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2021130638A1

  公开（公告）日：2021-07-01

  The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。
• A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways
  作者：Sarah Wagner-Griffin、Masahito Abe、Raphael I. Benhamou、Alicia J. Angelbello、Kamalakannan Vishnu、Jonathan L. Chen、Jessica L. Childs-Disney、Matthew D. Disney

  DOI：10.1021/acs.jmedchem.1c00414

  日期：2021.6.24

  Myotonic dystrophy type 2 (DM2) is one of >40 microsatellite disorders caused by RNA repeat expansions. The DM2 repeat expansion, r(CCUG)exp (where “exp” denotes expanded repeating nucleotides), is harbored in intron 1 of the CCHC-type zinc finger nucleic acid binding protein (CNBP). The expanded RNA repeat causes disease by a gain-of-function mechanism, sequestering various RNA-binding proteins including

  2 型强直性肌营养不良 (DM2) 是由 RNA 重复扩增引起的 >40 种微卫星疾病之一。DM2 重复扩增 r(CCUG) exp（其中“exp”表示扩增的重复核苷酸）包含在 CCHC 型锌指核酸结合蛋白 (CNBP) 的内含子 1 中。扩展的 RNA 重复通过功能获得机制引起疾病，隔离各种 RNA 结合蛋白，包括前 mRNA 剪接调节因子 MBNL1。MBNL1 的隔离导致其功能丧失和随之而来的天然底物选择性剪接的失调。值得注意的是，该 r(CCUG) exp导致成熟 CNBP mRNA 中内含子 1 的保留。在此，我们报告了与 r(CCUG) exp采用的结构结合的药物样小分子并改善 DM2 相关缺陷。这些小分子通过筛选来自以 RNA 为重点的小分子文库的命中进行优化，以提供一种化合物，该化合物可特异性结合 r(CCUG) exp并具有纳摩尔亲和力，促进其所在的异常保留内含子的内源性降解，并拯救选择性剪接缺陷。
• [EN] IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE PRÉSENTANT DES PROPRIÉTÉS ANTAGONISTES DU A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2019118313A1

  公开（公告）日：2019-06-20

  Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  本文披露了具有Formula I结构的化合物，或者其任何药学上可接受的盐：其中：“Z”和R1在此有定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度发现的受体。据信，这些化合物和药物配方在治疗或管理神经退行性疾病，例如帕金森病，或由于使用治疗或管理帕金森病的某些药物而引起的运动障碍方面是有用的。
• ALKYNYL ALCOHOLS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20150057260A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein A 1 -A 8 , R 4 and R 5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及具有以下结构的化合物（0）：其中A1-A8，R4和R5分别具有如本文所述的含义。 公式（0）的化合物及其药物组成物在治疗观察到NF-kB信号不受欢迎或过度激活的疾病和紊乱中是有用的。